Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Groot, S.M. de

Search results

  • RSS Feed
(1 - 8 of 8)
Genetic polymorphisms (SNPs) as predictive markers for paclitaxel-induced peripheral neuropathy (PNP) and capecitabine-induced hand-foot syndrome (HFS) in HER-2 negative metastatic breast cancer patients
Lam, S.W.; Frederiks, C.N.; Straaten, T. van der; Groot, S.M. de; Jager, A.; Bos, M.M.E.M.; ... ; E. boven 2015
Genetic polymorphisms (SNPs) as predictive markers for paclitaxel-induced peripheral neuropathy (PNP) and capecitabine-induced hand-foot syndrome (HFS) in HER-2 negative metastatic breast cancer patients
Article / Letter to editor
metadata only
Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
Lam, S.W.; Nota, N.M.; Groot, S.M. de; Jager, A.; Bos, M.M.; Linn, S.C.; ... ; E. boven 2015
Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
Article / Letter to editor
metadata only
Results from a randomized phase II study of the Dutch Breast Cancer Research Group (BOOG 2008-03): Concomitant trastuzumab, bevacizumab and paclitaxel (HAT) versus trastuzumab and bevacizumab, followed by trastuzumab, bevacizumab and paclitaxel (HA- HAT)
Drooger, J.C.; Tinteren, H. van; Groot, S.M. de; Tije, A.J. ten; Graaf, H. de; Portielje, J.E.A.; ... ; Sleijfer, S. 2015
Results from a randomized phase II study of the Dutch Breast Cancer Research Group (BOOG 2008-03): Concomitant trastuzumab, bevacizumab and paclitaxel (HAT) versus trastuzumab and bevacizumab, followed by trastuzumab, bevacizumab and paclitaxel (HA- HAT) a
Article / Letter to editor
metadata only
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
Lam, S.W.; Groot, S.M. de; Honkoop, A.H.; Jager, A.; Tije, A.J. ten; Bos, M.M.E.M.; ... ; Dutch Breast Canc Res Grp BOOG 2014
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
Article / Letter to editor
metadata only
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG
Smorenburg, C.H.; Groot, S.M. de; Leeuwen-Stok, A.E. van; Hamaker, M.E.; Wymenga, A.N.; Graaf, H. de; ... ; Seynaeve, C. 2014
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG
Article / Letter to editor
metadata only
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group
Hamaker, M.E.; Seynaeve, C.; Wymenga, A.N.M.; Tinteren, H. van; Nortier, J.W.R.; Maartense, E.; ... ; Smorenburg, C.H. 2014
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group
Article / Letter to editor
metadata only
Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
Lam, S.W.; Groot, S.M. de; Honkoop, A.H.; Nota, N.M.; Jager, A.; Velden, A.M.T. van der; ... ; Dutch Breast Canc Trialists' Grp B 2013
Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
Article / Letter to editor
metadata only
Feasibility and Toxicities Associated with PEG Doxo Versus Capecitabine as First-line Chemotherapy in Elderly Metastatic Breast Cancer (MBC) Patients; Results From the Randomized OMEGA Study of the Dutch Breast Cancer Trialists' Group (BOOG)
Seynaeve, C.; Tinteren, H. van; Wymenga, A.N.M.; Nortier, J.W.R.; Maartense, E.; Jongh, F.E. de; ... ; Smorenburg, C. 2012
Feasibility and Toxicities Associated with PEG Doxo Versus Capecitabine as First-line Chemotherapy in Elderly Metastatic Breast Cancer (MBC) Patients; Results From the Randomized OMEGA Study of the Dutch Breast Cancer Trialists' Group (BOOG)
Article / Letter to editor
metadata only